Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2
Eligible age
18–80 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The investigators are studying the pathophysiologic links between obesity, insulin resistance (IR), adipose tissue infection, and post-acute sequelae of COVID-19 (PASC). This study looks at whether adipose (fat) tissue contributes to PASC by driving chronic inflammation or by serving as a reservoir for SARS-CoV-2 persistence. The results will not only determine whether obesity and IR are risk factors for PASC, but will also define fundamental biology that sets the stage for the investigation of novel or existing therapies that target the causal pathways identified.
Sponsor: Stanford University
You may qualify if…
- ✓ Ages 18 to 80
- ✓ BMI ≥ 25 kg/m2
- ✓ not currently pregnant
You may not qualify if…
- ✕ Arm 2 (Adipose Tissue Biopsy) exclusions include
- ✕ pregnancy
- ✕ prior liposuction
- ✕ recent change in weight (\> 2 kg in one month)
- ✕ bleeding disorders
- ✕ anticoagulant use
- ✕ Arm 3 (healthy controls only) exclusions include patients with
- ✕ major organ disease
Where it's recruiting
Palo Alto
Source: ClinicalTrials.gov · NCT05833217 · last updated 2024-12-04